Biomarkers

The study suggests commonly available lab tests might help identify intestinal fibrosis and strictures in Crohn’s disease using a five-marker blood-based model, which could offer a noninvasive screening option if...

Patients and clinicians want blood or noninvasive tests that reflect what is seen on colonoscopy. This study identifies XCL1 as a blood biomarker candidate associated with endoscopic activity in Crohn's disease, though...

Accurate diagnosis and classification affect treatment choices and risks—misdiagnosis can lead to unnecessary immunosuppression, while misclassification can under-recognize severe or proximal disease that needs different...

If oral microbes can influence the gut, that could open new ways to monitor or modify disease activity in IBD (for example saliva-based biomarkers or oral-targeted interventions). It also highlights modifiable factors...

A simple blood test (CRP) that's already used in IBD care might help predict which Crohn's patients with C. difficile coinfection are more likely to need intestinal surgery, enabling earlier attention or monitoring.

IBD is linked to higher skeletal risk; early biochemical changes in Wnt-pathway proteins might identify bone impairment before DXA detects low bone density, potentially helping earlier risk stratification.

These patient-derived human tissue models aim to let drug developers test whether a candidate affects disease-relevant biology in human intestinal tissue before moving to clinical trials, which could help reduce failures...

Stronger, more sustainable IBD research units can increase patient access to clinical studies, speed up therapeutic and biomarker advances, and make care more research-ready. Patients and clinicians in centers with...

Distinguishing inflammation from irreversible fibrosis is a common clinical challenge in Crohn’s disease because it affects treatment choices (medical therapy versus surgery). Validated MRI biomarkers could improve...

Perianal fistulizing Crohn's disease is a frequent, hard-to-treat complication; molecular and multiomic advances could lead to biomarkers that help choose better-targeted therapies and improve surgical–medical decision...

The gut microbiome and its metabolic pathways are areas of active research in IBD; this study suggests specific genera and predicted functions that could become candidate biomarkers or targets for follow-up studies.

Parents and clinicians often worry about liver disease when children are diagnosed with Crohn's. This study suggests advanced liver fibrosis is uncommon at diagnosis, but elastography and fibrotic biomarkers can be...

Noninvasive biomarkers that predict response to anti‑TNF drugs could help personalize treatment decisions and identify early who will achieve long‑term endoscopic remission.

Pyroptosis is a key inflammatory pathway that may drive or modulate IBD activity. Understanding and targeting it could lead to new treatments, but past trial setbacks mean patients should know translation is still...

New Phase 2b maintenance data suggest a novel anti‑TL1A antibody may provide sustained symptom relief and mucosal improvement for some people with moderate-to-severe UC or CD — outcomes that matter because durable...

Early-phase data suggest PALI-2108 reaches the ileum and colon and produced rapid reductions in endoscopic inflammation and fecal calprotectin in small Phase 1b cohorts—results that could matter if confirmed in larger...

If confirmed in later trials, a new TL1A‑targeting antibody could add a novel mechanism for patients with UC or Crohn’s who do not respond adequately to current therapies. Durable clinical and endoscopic responses over...

Biomarkers of gut barrier integrity and oxidative stress could reveal hidden inflammation, help predict disease progression, and indicate likely treatment response—steps toward more personalized IBD care.

Patients and clinicians worry isotretinoin might trigger flares in people with existing IBD. This study suggests that among patients with stable, well-controlled Crohn's or UC, isotretinoin did not generally worsen...

This study identifies a compound that improved inflammation, barrier integrity, and microbiome/metabolite signatures in a mouse model of ulcerative colitis—areas that matter for symptom control and disease biology in...

Identifying a blood biomarker that appears before symptoms could help find people at higher risk for Crohn’s disease and improve understanding of early disease processes. This could inform earlier monitoring or future...

A blood biomarker that predicts anti-TNF response could help people with IBD and their clinicians choose the right biologic sooner, avoiding ineffective treatment. This study reports that lower baseline serum oncostatin...

This study tested a blood biomarker (zonulin) tied to gut barrier function and found no evidence of increased intestinal permeability in these Behçet syndrome patients, unlike in the Crohn’s disease group.

Multi-omics and AI approaches could improve biomarker discovery and predictive models that matter for earlier diagnosis and personalised treatment strategies in IBD, but practical use is limited today by data and...

This study uses transcriptomics, single‑cell data, and machine learning to nominate lactylation‑related genes as biomarkers and drug targets in ulcerative colitis, which could guide future biomarker or drug‑repurposing...

Blood platelet indices (PLR, MPV) are simple blood-test measures that may help detect IBD activity and show changes with biologic treatment. If validated, they could offer an inexpensive, noninvasive way to supplement...

IUS with the IBUS‑SAS score may offer a reliable, noninvasive way to monitor Crohn’s disease activity that correlates with clinical scores and biomarkers and aligns well with CT/MRI for most findings.

Based on the title and source metadata, this appears to be a systematic review or meta analysis related to Crohn's disease, Inflammatory bowel disease, and Biomarkers. The original article is from Frontiers in medicine.

The findings suggest that tissue-based immune profiling may better identify biologically distinct subgroups in ulcerative colitis than blood tests, which could affect research on personalized treatment or trial...

This study aims to measure how much time people with ulcerative colitis spend with objectively uncontrolled inflammation and to compare real-world outcomes of different initial advanced-therapy choices and...

A blood biomarker that reflects transmural inflammation could help monitor small-bowel Crohn’s disease noninvasively and might predict risk of rehospitalization.

The trial tests a naturally derived oral supplement (WPMDE2) in patients with ulcerative colitis, measuring symptoms, inflammatory markers, and quality of life—outcomes that matter to people living with IBD. Early-phase...

Cardiovascular disease is an important extraintestinal concern for people with IBD, and current risk scores may miss IBD-specific drivers. This study aims to track heart and vascular events in IBD and find biomarkers...

Deep remission is an emerging treatment target in Crohn’s disease that combines symptoms and objective measures. A meaningful proportion of patients in VIVID-1 achieved corticosteroid-free deep remission with mirikizumab...

Phase 3 results suggest mirikizumab (Omvoh) can produce sustained, steroid-free remission-related outcomes at one year in both ulcerative colitis and Crohn’s disease, including in some patients who previously failed...

These results suggest mirikizumab can achieve multiple treatment goals at once — symptoms, objective inflammation measures, and steroid-free status — outcomes that matter to people with IBD because they reflect both...

Microbiota-derived metabolites are linked to inflammation and gut barrier function, so they could become biomarkers or therapeutic targets for Crohn’s disease and ulcerative colitis. Patients may see future tests or...

The review links ER stress and mitochondrial dysfunction to core IBD processes (inflammation, barrier damage, cell death) and highlights MERCs as an integrated signaling hub, suggesting new biomarker and therapeutic...

If confirmed, an existing diabetes drug class (SGLT2 inhibitors) could offer an adjunct anti-inflammatory option for people with mild-to-moderate ulcerative colitis and might affect symptoms, biomarkers, and quality of...

People with ulcerative colitis often face trial‑and‑error when starting advanced therapies. THAMES‑IBD aims to find biological and psychosocial markers that predict who will respond, which could eventually make treatment...

The study explores whether blood redox biomarkers relate to short- and long-term response to infliximab or vedolizumab, which could help predict who benefits from these biologics. It also suggests a link between...

RDW-CV, a routine blood-test parameter, may help signal higher inflammatory activity in ulcerative colitis and provide low-cost adjunctive information when assessing disease activity.

Wearable-derived digital biomarkers could enable earlier, less burdensome detection of IBD flares and better remote monitoring if they reliably predict mucosal inflammation.

The study suggests a decade-long preclinical phase of IBD detectable by blood metabolites, which could open opportunities for earlier identification of people at risk for Crohn’s disease and for studying early disease...

Early human data suggest PALI-2108 reaches intestinal tissue and produced short-term clinical, endoscopic, and biomarker changes in very small Phase 1 cohorts, supporting larger Phase 2 trials that could determine if...

A breath-based VOC test could offer a noninvasive, point-of-care way to help detect or screen for colon diseases including IBD. This study shows preliminary promise—especially for ulcerative colitis—but is early-stage...

Early Phase 1 findings suggest a gut-targeted PDE4 prodrug may engage its target in diseased tissue and produce early improvements in symptoms, endoscopy, and tissue inflammation — findings that, if confirmed in Phase 2,...

The review links microbiome, metabolites, barrier function, and immune responses across anorectal disorders and ulcerative colitis — areas that directly affect symptoms, healing, and response to therapy.